Evidence map›Paper›PMID 35065633›Full record

ArticleWorld journal of surgical oncology2022

High expression of PDZ-binding kinase is correlated with poor prognosis and immune infiltrates in hepatocellular carcinoma.

Wei Mu, Yaoli Xie, Jinhu Li, Runzhi Yan, Jingxian Zhang, Yu'e Liu, Yimin Fan

Open access · goldAbstract read
In one paragraph

Article in World journal of surgical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Wei Mu *Department of Neurosurgery, The First Hospital of Shanxi Medical University, Taiyuan, 030001, Shanxi, China.
Yaoli Xie *Department of Physiology, Shanxi Medical University, Taiyuan, 030001, Shanxi, China.
Jinhu LiDepartment of Neurosurgery, The First Hospital of Shanxi Medical University, Taiyuan, 030001, Shanxi, China.
Runzhi YanDepartment of Neurosurgery, The First Hospital of Shanxi Medical University, Taiyuan, 030001, Shanxi, China.
Jingxian ZhangDepartment of Interventional Radiology, Shanxi Provincial People's Hospital, Taiyuan, 030012, Shanxi, China.
Yu'e LiuDepartment of Interventional Radiology, Shanxi Provincial People's Hospital, Taiyuan, 030012, Shanxi, China.
Yimin FanDepartment of Neurosurgery, The First Hospital of Shanxi Medical University, Taiyuan, 030001, Shanxi, China. blueskyfan@126.com.
Shanxi Medical University · CNShaanxi Provincial People's Hospital · CNFirst Hospital of Shanxi Medical University · CN

Funding

Key R&D Projects of Shanxi Province 201803031149Scientific Research Project of Shanxi Provincial Health and Family Planning Commission 2015022
6 · The paper itself

Abstract

backgroundPDZ-binding kinase (PBK) encodes a serine/threonine protein kinase related to the dual specific mitogen-activated protein kinase kinase (MAPKK) family. There is evidence that overexpression of this gene is associated with tumorigenesis. However, the role of PBK in hepatocellular carcinoma (HCC) remains unclear. Therefore, we evaluated the prognostic role of PBK and its correlation with immune infiltrates in hepatocellular carcinoma.

methodsThe expression of PBK in pan-cancers was studied by Onconmine and TIMER. The expression of PBK in HCC patients and its relationship with clinicopathological characteristics were analyzed using The Gene Expression Profiling Interactive Analysis (GEPIA), The human protein atlas database (HPA), The Cancer Genome Atlas (TCGA), and Gene Expression Omnibus (GEO) databases. Receiver operating characteristic (ROC) curve was used to determine the diagnostic value of PBK in HCC patients. The relationship between PBK and prognosis of HCC was performed by GEPIA and Kaplan Meier plotter web tool. The correlations between the clinical characteristics and overall survival were analyzed by Univariate Cox regression and Multivariate Cox hazards regression to identify possible prognostic factors for HCC patients. LinkedOmics was applied to investigate co-expression associated with PBK and to analyze Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways. The network map of PBK and related genes is constructed by GeneMANIA. Finally, TIMER and TISIDB were used to analyze the correlations between PBK and tumor-infiltrating immune cells.

resultsMultiple database analysis shows that PBK was highly expressed in many types of tumors, including hepatocellular carcinoma, and was significantly related to tumor stage (P=0.0089), age (P=0.0131), and race (P=0.0024) of HCC patients. The receiver operating characteristic (ROC) curve analysis showed that PBK had high diagnostic potential to HCC in GSE76427 (AUC=0.8799), GSE121248 (AUC=0.9224), GSE62232 (AUC=0.9975), and GSE84402 (AUC=0.9541). Multivariate Cox hazards regression showed that high expression of PBK may be an independent risk factor for overall survival in HCC patients (HR = 1.566, 95% CI=1.062-2.311, P= 0.024). The Protein-protein interaction network showed that PBK significantly interacted with LRRC47, ARAF, LGALS9B, TTK, DLG1, and other essential genes. Furthermore, enrichment analysis showed that PBK and co-expressed genes participated in many biological processes, cell composition, molecular functions, and pathways in HCC. Finally, the immune infiltration analysis by TIMER and TISIDB indicated that a significant tightly correlation between PBK and macrophages, neutrophils, as well as chemokines and receptors.

conclusionsHigh expression of PBK is significantly correlated with poor survival and immune infiltrates in hepatocellular carcinoma. Our study suggests that PBK can be used as a biomarker of poor prognosis and potential immune therapy target in hepatocellular carcinoma.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsBiomarkers, TumorHumansMitogen-Activated Protein Kinase KinasesPrognosisBiomarkers, TumorMitogen-Activated Protein Kinase KinasesPDZ-binding kinaseBioinformatics analysisHepatocellular carcinoma (HCC)PDZ-binding kinase (PBK)Signaling pathwaysTumor-infiltrating immune cells (TIICs)

Identifiers

PMID35065633
PMCPMC8783494
OpenAlexW4207063464

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.